Oral PCSK9 Inhibitors

Anandita Agarwala,Ramsha Asim,Christie M. Ballantyne

DOI: https://doi.org/10.1007/s11883-024-01199-2

IF: 5.967

2024-03-28

Current Atherosclerosis Reports

Abstract:In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

peripheral vascular disease

What problem does this paper attempt to address?

New Oral PCSK9 Inhibitor: “MK-0616”

Zoya Siddiqui,William Frishman

DOI: https://doi.org/10.1097/crd.0000000000000655

2024-01-29

Cardiology in Review

Abstract:MK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia. Unlike current PCSK9 inhibitors, which are injectable monoclonal antibodies and siRNA molecules, MK-0616 offers a patient-friendly alternative. The development of MK-0616 involved innovative synthetic chemistry and in vitro mRNA display technology. This cutting-edge approach led to the creation of an orally administered peptide with the ability to cover a larger portion of PCSK9 compared to smaller, linear peptides. Phase 1 and 2b clinical trials have demonstrated MK-0616’s safety, efficacy, and pharmacokinetics. These trials indicate the drug’s dose-dependent systemic absorption and long half-life. Notably, MK-0616 has exhibited comparable low-density lipoprotein cholesterol-lowering effects to currently available PCSK9 inhibitors, all while maintaining good tolerability in diverse patient populations, including those concurrently on statin therapy. As MK-0616 advances to Phase 3 trials, its lipid-lowering potential for heterozygous familial hypercholesterolemia and its impact on reducing the time to adverse cardiac events will be evaluated in a broad and diverse population, including underrepresented groups. The results achieved so far are promising for individuals with hypercholesterolemia, as they offer a potential solution for effectively lowering low-density lipoprotein cholesterol in patients on statin therapy and mitigating the risk of cardiovascular events. Ongoing research and monitoring will be critical to establish its long-term safety and efficacy, but MK-0616 may emerge as a valuable addition to the array of lipid-lowering therapies available to patients.

cardiac & cardiovascular systems
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment

John R. Burnett,Amanda J. Hooper,John R. BurnettAmanda J. Hoopera Department of Clinical Biochemistry,PathWest Laboratory Medicine,Perth,Western Australiab Royal Perth Hospital & Fiona Stanley Hospital Network,Perth,Western Australiac School of Medicine,University of Western Australia,Perth,Western Australia

DOI: https://doi.org/10.1080/13543784.2023.2267972

2023-10-11

Expert Opinion on Investigational Drugs

Abstract:Introduction Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Lowering LDL-cholesterol, by lifestyle modification or therapeutically, reduces the risk of ASCVD. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which binds to the LDL-receptor and induces degradation, is a clinically validated target to lower LDL-cholesterol. Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased risk of ASCVD events.

pharmacology & pharmacy
PCSK9 Inhibition: From Current Advances to Evolving Future

Chunping Liu,Jing Chen,Huiqi Chen,Tong Zhang,Dongyue He,Qiyuan Luo,Jiaxin Chi,Zebin Hong,Yizhong Liao,Shihui Zhang,Qizhe Wu,Huan Cen,Guangzhong Chen,Jinxin Li,Lei Wang

DOI: https://doi.org/10.3390/cells11192972

IF: 6

2022-09-24

Cells

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to regulating LDL-R, PCSK9 inhibitors can also bind Toll-like receptors (TLRs), scavenger receptor B (SR-B/CD36), low-density lipoprotein receptor-related protein 1 (LRP1), apolipoprotein E receptor-2 (ApoER2) and very-low-density lipoprotein receptor (VLDL-R) reducing the lipoprotein concentration and slowing thrombosis. In addition to cardiovascular diseases, PCSK9 is also used in pancreatic cancer, sepsis, and Parkinson's disease. Currently marketed PCSK9 inhibitors include alirocumab, evolocumab, and inclisiran, as well as small molecules, nucleic acid drugs, and vaccines under development. This review systematically summarized the application, preclinical studies, safety, mechanism of action, and latest research progress of PCSK9 inhibitors, aiming to provide ideas for the drug research and development and the clinical application of PCSK9 in cardiovascular diseases and expand its application in other diseases.

cell biology
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part 2: Current and emerging concepts in the clinical use of PCSK9 inhibition

Alexander M. Cao Zhang,Efthymios Ziogos,Tarek Harb,Gary Gerstenblith,Thorsten M. Leucker

DOI: https://doi.org/10.1111/eci.14272

2024-06-27

European Journal of Clinical Investigation

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has shown to influence diverse physiologic pathways, including lipid metabolism, atherosclerotic plaque remodeling, and inflammation. This review explores the therapeutic implications of PCSK9 inhibitors beyond lipid regulation, highlighting their potential clinical use in acute coronary and extra‐coronary disease processes. Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a novel class of drugs with cardioprotective effects through their lipid‐lowering effects. Objective This review aims to discuss existing and novel strategies of PCSK9 inhibition, providing an overview of established randomized controlled trials and ongoing outcome trials that assess the efficacy and long‐term safety of PCSK9 inhibitors. It also explores the evolving role of PCSK9 beyond lipid metabolism and outlines the pleiotropic actions of PCSK9 inhibition in various disorders and future directions including novel strategies to target PCSK9. Conclusion PCSK9 inhibition shows promise not only in lipid metabolism but also in other disease processes, including atherosclerotic plaque remodeling, acute coronary syndrome, stroke, inflammation, and immune response.

medicine, general & internal, research & experimental
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations

Paulina Elena Stürzebecher,Ulrich Laufs

DOI: https://doi.org/10.1097/mol.0000000000000935

IF: 4.616

2024-03-30

Current Opinion in Lipidology

Abstract:Monoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations.

biochemistry & molecular biology,endocrinology & metabolism,peripheral vascular disease
Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Azita H Talasaz,Ai-Chen Jane Ho,Fawzia Bhatty,Rachel A Koenig,Dave L Dixon,William L Baker,Benjamin W Van Tassell

DOI: https://doi.org/10.1002/phar.2635

Pharmacotherapy

Abstract:The advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) ushered in a new era of dyslipidemia pharmacotherapy. The first two antibodies targeting PCSK9 (evolocumab, alirocumab) approved by the United States Food and Drug Administration (FDA) provided significant and sustained reductions in atherogenic lipids and a reduced risk of atherosclerotic cardiovascular disease (ASCVD) events. More recently, phase 3 trials of inclisiran-a small interfering RNA-based agent targeting PCSK9-reported similar lipid-lowering effects and preliminary evidence of ASCVD risk reduction, although significant questions remain regarding the extent of benefits across cardiovascular outcomes. We conducted a systematic review and meta-analysis (random-effects model) of the available data on lipid lowering, incidence of atherosclerotic cardiovascular disease (ASCVD) events, and safety of pharmacologic agents targeting PCSK9. A significant and consistent reduction in low-density lipoprotein cholesterol (LDL-C) was observed across all agents (-51% [95% confidence interval {CI}: -61%, -41%]). Despite the impressive reduction in LDL-C, the individual effects on mortality, cardiovascular death, myocardial infarction (MI), and stroke remained nonsignificant. However, a consistent reduction was observed in the composite outcomes of MI, stroke, and cardiovascular death [relative risk {RR} (95% CI): 0.80 (0.73-0.87)] and MI, stroke, unstable angina (requiring revascularization), and cardiovascular death [RR (95% CI): 0.85 (0.74-0.97)]. In terms of safety outcomes, there was no significant difference in severe adverse events, new onset diabetes, neurocognitive disorders, or myalgia. Meanwhile, injection site reaction was more frequent in patients receiving these agents compared to placebo [RR 2.11 (95% CI): 1.26-3.54]. These findings suggest a class effect for favorable lipid changes and a low risk of serious adverse events among pharmacologic agents targeting PCSK9. Although there is compelling evidence that PCSK9-targeting agents reduce the risk of some cardiovascular outcomes, adequately powered studies with longer follow-up may be needed to fully characterize the magnitude of benefits across the cardiovascular spectrum.
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

Daniel J McClintick,Robert P Giugliano

DOI: https://doi.org/10.1097/MOL.0000000000000897

2023-12-01

Abstract:Purpose of review: This article reviews PCSK9 inhibitors (PCSK9i) with a focus on clinically relevant studies published in the last 18 months. Recent findings: Prespecified subgroup evaluations, secondary analyses, and open-label extension studies from the two landmark trials, FOURIER and ODYSSEY Outcomes, have provided new data on the safety and efficacy of the monoclonal PCSK9 antibodies evolocumab and alirocumab. Recent studies of PCSK9i early in ACS and post percutaneous coronary intervention have explored early effects on biomarkers and plaque morphology with various imaging modalities. Two large outcome trials with PCSK9i in lower risk patients without prior myocardial infarction or stroke are ongoing and could expand the eligible population for these potent therapies. Additionally, novel methods to inhibit PCSK9 using oral administration, vaccination, and gene therapy are in various stages of clinical development. Summary: PCSK9i represent a potent class of lipid-lowering therapies that are well tolerated and effective in a wide group of patients with high-risk atherosclerotic cardiovascular disease. Ongoing studies of PCSK9i in patients at lower risk and with acute myocardial infarction have the potential to broaden their indication. Alternative methods of PCSK9i are being evaluated and could provide easier and less expensive options for this important class of medication.
PCSK9 Inhibition-Based Therapeutic Approaches: an Immunotherapy Perspective.

Amir Abbas Momtazi-Borojeni,Matteo Pirro,Suowen Xu,Amirhossein Sahebkar

DOI: https://doi.org/10.2174/0929867328666211027125245

IF: 4.74

2022-01-01

Current Medicinal Chemistry

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9-I) are novel therapeutic tools to decrease cardiovascular risk. These agents work by lowering the low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients who are statin resistant/intolerant. Current clinically approved and investigational PCSK9- I act generally by blocking PCSK9 activity in the plasma or suppressing its expression or secretion by hepatocytes. The most widely investigated method is the disruption of PCSK9/LDL receptor (LDLR) interaction by fully-humanized monoclonal antibodies (mAbs), evolocumab and alirocumab, which have been approved for the therapy of hypercholesterolemia and atherosclerotic cardiovascular disease (CVD). Besides, a small interfering RNA called inclisiran, which specifically suppresses PCSK9 expression in hepatocytes, is as effective as mAbs but with administration twice a year. Because of the high costs of such therapeutic approaches, several other PCSK9-I have been surveyed, including peptide-based anti-PCSK9 vaccines and small oral anti-PCSK9 molecules, which are under investigation in preclinical and phase I clinical studies. Interestingly, anti-PCSK9 vaccination has been found to serve as a more widely feasible and more cost-effective therapeutic tool over mAb PCSK9-I for managing hypercholesterolemia. The present review will discuss LDL-lowering and cardioprotective effects of PCSK9-I, mainly immunotherapy- based inhibitors including mAbs and vaccines, in preclinical and clinical studies.
A Review of PCSK9 Inhibitors and Their Effects on Cardiovascular Diseases

Bo Chen,Xin Shi,Yanping Cui,Aiping Hou,Pengjun Zhao

DOI: https://doi.org/10.2174/1568026619666190809094203

2019-01-01

Current Topics in Medicinal Chemistry

Abstract:Background: Cardiovascular diseases remain the leading cause of morbidity and mortality in the world, with elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels as the major risk factor. Lower levels of LDL-C can effectively reduce the risk of cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating the degradation of hepatic LDL receptors that remove LDL-C from the circulation. PCSK9 inhibitors are a new class of agents that are becoming increasingly important in the treatment to reduce LDL-C levels. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved to treat hypercholesterolemia and are available in the United States and the European Union. Through the inhibition of PCSK9 and increased recycling of LDL receptors, serum LDL-C levels can be significantly reduced. Objective: This review will describe the chemistry, pharmacokinetics, and pharmacodynamics of PCSK9 inhibitors and their clinical effects.
PCSK9 inhibitors: a patent review 2018-2023

Enrico Mario Alessandro Fassi,Andrea Citarella,Marco Albani,Erica Ginevra Milano,Laura Legnani,Carmen Lammi,Alessandra Silvani,Giovanni Grazioso

DOI: https://doi.org/10.1080/13543776.2024.2340569

2024-04-12

Expert Opinion on Therapeutic Patents

Abstract:Introduction Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in breaking down the hepatic low-density lipoprotein receptor (LDLR), thereby influencing the levels of circulating low-density lipoprotein cholesterol (LDL-C). Consequently, inhibiting PCSK9 through suitable ligands has been established as a validated therapeutic strategy for combating hypercholesterolemia and cardiovascular diseases.

pharmacology & pharmacy,chemistry, medicinal
PCSK9 inhibitors: A new era of lipid lowering therapy

Rahul Chaudhary,Jalaj Garg,Neeraj Shah,Andrew Sumner

DOI: https://doi.org/10.4330/wjc.v9.i2.76

2017-01-01

World Journal of Cardiology

Abstract:Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events. However, there are limited options for patients who are either intolerant to statin therapy, develop CVD despite being on maximally tolerated statin therapy, or have severe hypercholesterolemia. Recently the Food and Drug Administration approved two novel medications for low-density lipoprotein (LDL)-cholesterol reduction: Evolocumab and Alirocumab. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction. By preventing LDL receptor destruction, LDL-C levels can be lowered 50%-60% above that achieved by statin therapy alone. This review explores PCSK-9 biology and the mechanisms available to alter it; clinical trials targeting PCSK9 activity, and the current state of clinically available inhibitors of PCSK9.

English Else
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Xuhui Bao,Yongjun Liang,Hanman Chang,Tianji Cai,Baijie Feng,Konstantin Gordon,Yuekun Zhu,Hailian Shi,Yundong He,Liyi Xie

DOI: https://doi.org/10.1038/s41392-023-01690-3

IF: 39.3

2024-01-08

Signal Transduction and Targeted Therapy

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9's potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9's aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine.

biochemistry & molecular biology,cell biology
Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

GU Zhi-chun,LIU Xiao-yan,SHEN Long,NI Xiao-jun,ZHONG Han

2014-01-01

Abstract:The proprotein convertase subtilisin/kexin type 9(PCSK9) regulates cholesterol metabolism mainly by targeting the low-density lipoprotein receptor(LDLR) for degradation in the liver.Gain-of-function mutations in PCSK9 is one of the genetic causes of autosomal dominant hypercholesterolaemia.Conversely,lossof-function mutations are associated with lower concentrations of LDL cholesterol( LDL-C) and reduced coronary heart disease.Now,PCSK9 has emerged as a new drug target for the treatment of hypercholesterolemia.Two PCSK9 inhibitors of monoclonal antibody have completed phase Ⅱand phase Ⅲ clinical trials.This paper is a comprehensive review of the latest research advances in PCSK9 inhibitors of monoclonal antibody.
PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives

Jitendra Gupta,Reena Gupta

DOI: https://doi.org/10.2174/1874467216666221202144813

Abstract:Cardiovascular disorders (CVDs) are the leading cause of death worldwide and are accelerated via the low level of low-density lipoprotein-cholesterol (LDL-C). The proprotein convertase subtilis/kexin type9 (PCSK9), a vital regulator and a biomarker, circulates for the LDL-C and has the degradation capability of the low-density lipoprotein receptor (LDLR). PCSK9 has modulated the overall mechanism by transcription, secretion, clearance, or extracellular inactivation in the past few years.PCSK9 has specific pathophysiological roles in many cardiovascular cells. The initial data on the PCSK9 inhibitor, Evolocumab, has a specific reduction in the composite end-point, such as cardiovascular, myocardial, and stroke, while the rest of the data release is still under wait. Furthermore, it is witnessed that the U.S. and the European authorities have approved two humanized antibodies against the LDL-R binding site of PCSK9. This review highlighted the recent data findings on the PCSK9 and its regulation, focusing on cardiovascular disorders, and summarized the current clinical studies. Thus it provides a ray of hope to overcome statin intolerance and alternative approaches for PSCK9 inhibition and significantly reduce cardiovascular complications. This review plays a pivotal role for the researchers and scientists working on PCSK9 inhibitors to treat cardiovascular disorders.
PCSK9-directed therapies: an update

Julius L. Katzmann,Ulrich Laufs

DOI: https://doi.org/10.1097/mol.0000000000000919

IF: 4.616

2024-01-27

Current Opinion in Lipidology

Abstract:Two large cardiovascular outcomes trials of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) demonstrated that therapeutic inhibition of extracellular PCSK9 markedly reduces LDL cholesterol concentration and cardiovascular risk. Several novel strategies to inhibit PCSK9 function are in development. Different mechanisms of action may determine specific properties with potential relevance for patient care.

biochemistry & molecular biology,endocrinology & metabolism,peripheral vascular disease
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9

Alexander M. Cao Zhang,Efthymios Ziogos,Tarek Harb,Gary Gerstenblith,Thorsten M. Leucker

DOI: https://doi.org/10.1111/eci.14273

2024-06-27

European Journal of Clinical Investigation

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) exhibit diverse pro‐atherosclerotic effects, impacting circulating lipoprotein variables, non‐LDL receptors and key cell types involved in atherosclerotic plaque formation. Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily recognized for its role in lipid metabolism, but recent evidence suggests that it may have broader implications due to its diverse tissue expression. Objective This review aims to explore the multifaceted functions of PCSK9, highlighting its pro‐atherosclerotic effects, including its impact on circulating lipoprotein variables, non‐low‐density lipoprotein receptors, and various cell types involved in atherosclerotic plaque development. Conclusions PCSK9 exhibits diverse roles beyond lipid metabolism, potentially contributing to atherosclerosis through multiple pathways. Understanding these mechanisms could offer new insights into therapeutic strategies targeting PCSK9 for cardiovascular disease management.

medicine, general & internal, research & experimental
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events

Muharrem Akin,Thomas Skripuletz,L Christian Napp,Dominik Berliner,Ibrahim Akin,Arash Haghikia,Elvan Akin,Johann Bauersachs

DOI: https://doi.org/10.2174/1871525714666160727113740

Abstract:Statins are the most widely prescribed drugs to reduce serum low density lipoprotein cholesterol (LDL-C) by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. LDL-C reduction is associated with a decreased risk of atherosclerotic cardiovascular disease (ASCVD), including cardiovascular disease (CVD) and stroke. Statins reduce LDL-C by 30 to 40%, and the combination with other lipid-lowering agents such as ezetimibe leads to a further reduction by 20 to 25%. However, even the combination of these two agents might not be sufficient in high risk patients to require aggressive LDL-C reduction. Therefore, starting from observations on individuals with loss-of-function in proprotein convertase subtilisin/kexin type 9 (PCSK9), which was associated with lower LDL-C levels and CVD rates, monoclonal antibodies (mAbs) against PCSK9 were developed. To date, two mAbs, alirocumab and evolocumab, have received approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the present review we give an overview about pathophysiological and clinical aspects as well as evidence for these drugs with respect to cerebrovascular events.
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

Willemijn A. M. Schonck,Erik S. G. Stroes,G. Kees Hovingh,Laurens F. Reeskamp

DOI: https://doi.org/10.1007/s40265-024-01995-9

2024-01-26

Drugs

Abstract:Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL-C have been the cornerstone of ASCVD prevention for decades. However, guideline-recommended LDL-C targets are not achieved in about 60% of statin users. Proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapy effectively lowers LDL-C levels and has been shown to reduce ASCVD risk. A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence of side effects in the short term. In this review, we present and discuss the current clinical and scientific evidence pertaining to the long-term efficacy and tolerability of PCSK9-targeted therapy.

pharmacology & pharmacy,toxicology
Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes

Moiud Mohyeldin,Ahmed S Abuelgasim,Ahmed Mg Mustafa

DOI: https://doi.org/10.4330/wjc.v16.i7.397

2024-07-26

Abstract:Peripheral artery disease (PAD) is a common condition characterized by atherosclerosis in the peripheral arteries, associated with concomitant coronary and cerebrovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of drugs that have shown potential in hypercholesterolemic patients. This review focuses on the efficacy, safety, and clinical outcomes of PCSK9 inhibitors in PAD based on the literature indexed by PubMed. Trials such as FOURIER and ODYSSEY demonstrate the efficacy of evolocumab and alirocumab in reducing cardiovascular events, offering a potential treatment option for PAD patients. Safety evaluations from trials show few adverse events, most of which are injection-site reactions, indicating the overall safety profile of PCSK9 inhibitors. Clinical outcomes show a reduction in cardiovascular events, ischemic strokes, and major adverse limb events. However, despite these positive findings, PCSK9 inhibitors are still underutilized in clinical practice, possibly due to a lack of awareness among care providers and cost concerns. Further research is needed to establish the long-term effects and cost-effectiveness of PCSK9 inhibitors in PAD patients.
PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis

Adi Prasad Bodapati,Ayesha Hanif,Donatus K Okafor,Gitika Katyal,Gursharan Kaur,Hafsa Ashraf,Safeera Khan

DOI: https://doi.org/10.7759/cureus.46605

2023-10-06

Cureus

Abstract:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved to treat dyslipidaemia. However, there is a lack of knowledge on the most efficient PCSK9 therapies that target PCSK9 for secondary prevention in subjects at high risk for cardiovascular (CV) events. Thus, this study aimed to assess the efficacy and safety of anti-PCSK9 antibodies in randomized controlled trials (RCTs). A comprehensive review of the available literature was done to identify RCTs that compared the use of PCSK9 inhibitors coupled with placebo or ezetimibe for the secondary prevention of CV events in patients on statin-background therapy. All-cause mortality was the major efficacy endpoint, while severe adverse events were the key safety outcome. A random effects model was used, and data were presented as risk ratio (RR) or risk difference with their corresponding 95% confidence intervals (CI). The heterogeneity of the publications was determined using Cochran's Q test, and publication bias was visually examined using funnel plots. All the chosen studies' quality was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI). Forty-one studies (76,304 patients: 49,086 on evolocumab, and 27,218 on alirocumab) were included, and their years of publication spanned from 2010 to 2023. Overall, no significant differences were observed in CV and all-cause mortality between PCSK9 inhibitors and controls. However, alirocumab use was linked to a reduced risk of all-cause death compared to control, but not evolocumab. Each of the drugs, evolocumab and alirocumab, significantly reduced the risk of myocardial infarction (MI), coronary revascularization, and ischemic stroke. In comparison to the control therapy, the risk of major detrimental sequelae was significantly reduced by alirocumab therapy in the subgroup analysis of each PCSK9 inhibitor, whereas evolocumab treatment did not demonstrate significant differences (RR = 0.88; 95% CI = 0.72-1.04; evolocumab: RR = 0.99; 95% CI = 0.87-1.11). Both evolocumab and alirocumab are well-tolerated, safe medications that significantly lower low-density lipoprotein (LDL) levels.

Oral PCSK9 Inhibitors

New Oral PCSK9 Inhibitor: “MK-0616”

MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment

PCSK9 Inhibition: From Current Advances to Evolving Future

Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part 2: Current and emerging concepts in the clinical use of PCSK9 inhibition

Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

PCSK9 Inhibition-Based Therapeutic Approaches: an Immunotherapy Perspective.

A Review of PCSK9 Inhibitors and Their Effects on Cardiovascular Diseases

PCSK9 inhibitors: a patent review 2018-2023

PCSK9 inhibitors: A new era of lipid lowering therapy

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

Proprotein Convertase Subtilism/kexin Type 9 Inhibitors: a New Strategy of Regulating Cholesterol

PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives

PCSK9-directed therapies: an update

Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events

Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes

PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis